- Previous Close
44.42 - Open
43.46 - Bid 30.96 x 200
- Ask 52.83 x 200
- Day's Range
41.22 - 43.73 - 52 Week Range
25.93 - 62.40 - Volume
1,704,603 - Avg. Volume
1,590,952 - Market Cap (intraday)
7.721B - Beta (5Y Monthly) 1.40
- PE Ratio (TTM)
-- - EPS (TTM)
-3.66 - Earnings Date Feb 24, 2025 - Feb 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
73.43
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
www.revmed.comRecent News: RVMD
View MorePerformance Overview: RVMD
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RVMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RVMD
View MoreValuation Measures
Market Cap
7.72B
Enterprise Value
6.26B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.98k
Price/Book (mrq)
4.93
Enterprise Value/Revenue
8.43k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.56%
Return on Equity (ttm)
-47.18%
Revenue (ttm)
742k
Net Income Avi to Common (ttm)
-567.06M
Diluted EPS (ttm)
-3.66
Balance Sheet and Cash Flow
Total Cash (mrq)
1.55B
Total Debt/Equity (mrq)
5.54%
Levered Free Cash Flow (ttm)
-306.13M